Inflammatory bowel diseases (IBD) manifest not only in the gastrointestinal (GI) tract, but also affect joints, skin, eyes, liver, lung, and pancreas. Up to half of patients with IBD have extraintestinal manifestations (EIMs) of IBD. Therapies for intestinal inflammation are not sufficient to treat EIMs such as anterior uveitis, ankylosing spondylitis, and primary sclerosing cholangitis (PSC), which usually occur independent of disease flares. In the October issue of Gastroenterology, Gerhard Rogler et al review the epidemiology, pathophysiology, clinical presentation, and treatment of EIMs in patients with IBD.
Trending
- GI 2.0: The Playbook | Industry Perspectives
- Disorders of Gut–Brain Interaction and the Rome V Process (Gastroenterology)
- Physician triage changed management in nearly 1 in 4 GI referrals (GI & Hepatology News)
- Upper GI Disorders: New Evidence May Refine Clinical Practice (Medscape)
- Pennsylvania Sues Chatbot Over Claims It Impersonates Doctors (MedCity News)
- Physician independence vanishes as corporate medicine swallows up U.S. health care (Medical Economics)
- Oshi Health Appoints Danny Krifcher as President and Chief Operating Officer (PR Newswire)
- Better onboarding may help GI practices retain APPs (GI & Hepatology News)
